Pregabalin is NOT Recommended for Primary Insomnia Treatment
Pregabalin should not be used as a treatment for primary insomnia. The FDA has not approved pregabalin for insomnia, and the most recent high-quality clinical practice guidelines explicitly recommend against using anticonvulsants like pregabalin for this indication 1, 2.
Why Pregabalin Should Not Be Used
The 2017 American Academy of Sleep Medicine clinical practice guideline specifically evaluated anticonvulsants for insomnia and recommended against using tiagabine (another anticonvulsant) for sleep onset or maintenance insomnia 1. While pregabalin was not directly evaluated in this guideline, the evidence base does not support its use for primary insomnia.
The 2016 American College of Physicians guideline similarly found insufficient evidence for using anticonvulsants in chronic insomnia disorder 2.
FDA-Approved Indications and Dosing
Pregabalin is FDA-approved for 3:
- Neuropathic pain (diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury)
- Fibromyalgia
- Adjunctive therapy for partial-onset seizures
NOT for insomnia.
Standard Dosing for Approved Indications
When pregabalin is used for its approved indications (which may secondarily improve sleep):
- Neuropathic pain: Start 50 mg three times daily (150 mg/day), increase to 300 mg/day within 1 week 4, 3
- Maximum dose: 600 mg/day in divided doses, though doses above 300 mg/day show limited additional benefit with increased side effects 4
The Sedation Side Effect Context
Pregabalin does cause dose-dependent sedation and dizziness as common adverse effects 4, 5. The guidelines note that "a sedating drug may be useful in a patient in whom insomnia is a problem" when treating pain conditions 6. However, this refers to leveraging a side effect when treating an approved indication—not using pregabalin primarily for insomnia.
Limited Research Evidence
While some research studies have explored pregabalin's effects on sleep:
- Studies in epilepsy patients with insomnia showed improved sleep continuity at 150 mg twice daily (300 mg/day total) 7, 8
- A study in hypnotic-dependent insomnia used 75-300 mg/day for withdrawal support 9
- Studies in anxiety disorders showed sleep improvement at 300-600 mg/day 10
Critical limitation: These studies involved patients with other primary conditions (epilepsy, anxiety, benzodiazepine dependence)—not primary insomnia. A 2022 systematic review concluded there is minimal evidence for gabapentinoids in insomnia 11.
What Should Be Used Instead
For chronic insomnia, evidence-based first-line treatments include 1, 2:
Non-pharmacologic (preferred):
- Cognitive behavioral therapy for insomnia (CBT-I)
Pharmacologic options with evidence:
- Eszopiclone: 2-3 mg at bedtime
- Zolpidem: 10 mg at bedtime (5 mg in elderly)
- Suvorexant: 10-20 mg at bedtime
- Doxepin: 3-6 mg at bedtime (for sleep maintenance)
- Ramelteon: 8 mg at bedtime (for sleep onset)
Critical Safety Concerns
- Abuse potential: Pregabalin is a Schedule V controlled substance with documented abuse liability, particularly in patients with insomnia 12
- Withdrawal symptoms: Discontinuation causes rebound insomnia and neurological symptoms 9, 12
- Dose-dependent adverse effects: Dizziness (55% at 150 mg twice daily), sedation, cognitive impairment 13
- Lack of long-term safety data for insomnia use
The Bottom Line
Using pregabalin for insomnia represents off-label use without supporting evidence from major sleep medicine guidelines, carries significant risks including dependence, and has FDA-approved alternatives with established efficacy. If a patient presents requesting pregabalin for insomnia, redirect to evidence-based treatments 1, 2. If insomnia occurs in the context of neuropathic pain or fibromyalgia where pregabalin is indicated, the standard dosing for those conditions (starting 150 mg/day, target 300 mg/day) may secondarily improve sleep 6, 4.